Abstract
Insulin resistance—an essential component of the metabolic syndrome—has been known for nearly 70 years. During the last 25 years numerous studies have shown that insulin resistance tend to occur concomitantly with a cluster of cardiovascular risk factors including increased blood pressure, lipid levels, obesity and a wide range of other factors associated with increased risk of developing CVD. This clustering of risk factors have been given many names, but during the last 10–15 years the label “Metabolic Syndrome” has been used as the common name for the condition. The definition has changed over time, and consequently it is difficult to compare epidemiological studies over time or between regions, as they have often used different definitions.
Independent of ethnicity, the prevalence of the metabolic syndrome increases by age. There are distinct effects of ethnicity, where the age-adjusted prevalence of the metabolic syndrome is highest in East-Asia and in the Middle East region. Within countries there are also marked differences with higher prevalence in Afro-American and Mexican-Hispanic groups than in white Caucasian groups in USA.
Based on a number of epidemiological studies, the clinical value of the “Metabolic Syndrome” has been questioned. The clinical relevance here refers to the issue—whether the presence of the metabolic syndrome predicts adverse outcome like diabetes and CVD, and whether it does so over and above the effect of the individual risk factors. Most studies indicate that it is the presence of the individual risk factors, not the syndrome that carries the clinically relevant information. Consequently, the syndrome may be a convenient term for a clustering of risk factors, but it seems to have limited clinical impact as an entity in itself.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Himsworth H (1936) Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1:127–130
Yalow RS, Berson SA (1960) Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immunoassay technique. Diabetes 9:254–260
Avogaro P, Crepaldi G, Enzi G, Tiengo A (1967) Associazione di iperlidemia, diabete mellito e obesita di medio grado. Acto Diabetol Lat 4:36–41
Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL (1983) Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol 188:326–337
Stern MP, Haffner SM (1986) Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Atherosclerosis 6:123–130
Ferrannini E, Buzzigoli G, Bonadornna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S (1987) Insulin resistance in essential hypertension. N Engl J Med 317:350–357
Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607
World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. WHO, Geneva
Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Diabetologia 48:1684–1699
Nakagami T, Qiao Q, Carstensen B, Nøhr-Hansen C, Hu G, Tuomilehto J, Balkau B, Borch-Johnsen K (2003) The DECODE-DECODA Study Group. Age, body mass index and Type 2 diabetes—associations modified by ethnicity. Diabetologia 46:1063–1070
Saad MF, Lilloja S, Nyomba BL et al (1991) Racial differences in the relation between blood pressure and insulin resistance. N Eng J Med 324:733–739
Lee CM, Huxley RR, Woodward M et al (2008) The metabolic syndrome identifies a heterogeneous group of metabolic component combinations in the Asia-Pacific region. Diabetes Res Clin Pract 8:377–380
NCEP (2001) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497
Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443
Al-Daghri NM (2010) Extremely high prevalence of metabolic syndrome manifestations among Arab youth: a call for early intervention. Eur J Clin Invest 40:1063–1066
Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P (2003) Prevalence of the metabolic syndrome among Omani adults. Diabetes Care 26:1781–1785
Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V (2002) Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross sectional evaluation. Atherosclerosis 165:285–292
Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716
Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K (2003) Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract 61:69–76
Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH (2008) Prevalence of the metabolic syndrome among US adolescents using the definition from the international diabetes federation. Diabetes Care 31:587–589
Meigs JB, Wilson PWF, Nathan DM, D’Agostino RB, Williams K, Haffner SM (2003) Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52:2160–2167
Li JB, Wang X, Zhang JX, Gu P, Zhang X, Chen CX, Guo R, Wu M (2010) Metabolic syndrome: prevalence and risk factors in southern China. J Int Med Res 38:1142–1148
Cai H, Huang J, Xu G, Yang Z, Liu M, Mi Y, Liu W, Wang H, Qian D (2012) Prevalence and determinants of metabolic syndrome among women in Chinese rural areas. PLoS One 7(5):e36936
Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359
Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Heine R, Wareham NJ, DECODE Study Group (2005) Are insulin resistance, impaired fasting glucose and impaired glucose tolerance all equally strongly related to age? Diabet Med 22:1476–1481
Hu G, Qiao Q, Tuomilehto J et al (2004) Prevalence of the metabolic syndrome and its relation to all-cause mortality in non-diabetic European men and women. Arch Intern Med 164:1066–1076
Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyörälä K, DECODE Insulin Study Group (2004) Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 47:1245–1256
Gu D, Reynolds K, Wu X et al (2005) Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365:1398–1405
Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27:2444–2449
Wasir JS, Misra A, Vikram NK, Pandey RM, Gupta R (2008) Comparison of definitions of the metabolic syndrome in adult Asian Indians. J Assoc Physicians India 56:158–164
Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927–1935
Lindström J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731
Glümer C, Carstensen B, Sandbæk A, Lauritzen T, Jørgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening. Diabetes Care 27:727–733
Stern MP et al (2004) Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease. Diabetes Care 27:2676–2681
Stern MP, Williams K, Haffner SM (2002) Identification of individuals at high risk of type 2 diabetes: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581
Haffner SM, Miettenen H, Gaskill SP, Stern MP (1990) Metabolic predictors of hypertension: the San Antonio Heart Study. Arch Intern Med 156:1994–2000
Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med 344:1343–1350
Pan X, Li G, Hu Y et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care 20:537–44
The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 346:393–403
Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K (2000) Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 20:538–544
Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689
Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M, S Group and the AFCAPS/TexCAPS Research Group (2004) The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93:136–141
Eddy DM, Schlessinger L, Heikes K (2008) The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes 32(Suppl 2):S5–S10
Herman WH, Smith PJ, Thomson TJ, Engelgau MM, Aubert RE (1995) A new and simple questionnaire to identify people at increased risk of undiagnosed diabetes. Diabetes Care 18:382–387
Ruige JB, Neeling JND, Kostence PJ, Bouter LM, Heine RJ (1997) Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 20:491–496
Baan CA, Ruige JB, Stolk RP, Witteman JC, Dekker JM, Heine RJ, Feskens EJ (1999) Performance of a predictive model to indentify undiagnosed diabetes in a health care setting. Diabetes Care 22:213–219
Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ (2000) Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice. Diabetes Metab Res Rev 16:164–171
Christensen JO, Sandbaek A, Laurtizen T, Borch-Johnsen K (2004) Population-based stepwise screening for unrecognised type 2 diabetes ineffective in general practice despite reliable algorithms. Diabetologia 47:1566–1573
Conroy RM, Pyörälä K, Fitzgerald AP et al (2003) Estimation of 10-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003
Hanson RL, Imperatore G, Bennett PH, Knowler WC (2002) Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 51:3120–3127
Ford ES (2005) Risk for all-cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778
Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB (2005) Metabolic Syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112:3066–3072
Meigs JB (2006) Metabolic Syndrome and risk for type 2 diabetes. Expert Rev Endocrinol Metab 1:57–66
Burke JP, Williams K, Haffner SM, Villalpando CG, Stern MP (2001) Elevated incidence of type 2 diabetes in San Antonio, Texas, compared with that of Mexico City, Mexico. Diabetes Care 24:1573–1578
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Wien
About this chapter
Cite this chapter
Borch-Johnsen, K. (2013). Epidemiology of the Metabolic Syndrome. In: Beck-Nielsen, H. (eds) The Metabolic Syndrome. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1331-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1331-8_2
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1330-1
Online ISBN: 978-3-7091-1331-8
eBook Packages: MedicineMedicine (R0)